Summit Therapeutics Inc. (SMMT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX 
Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You?
Millennium Management just initiated a position in a small biotech company developing a new cancer drug.
Up 700% This Year, Is It Too Late to Invest in This Stock?
The shares have experienced a pullback in the past couple of weeks.
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
It's hard to go wrong with either company, but one is more appealing.
3 Things You Need to Know If You Buy Summit Therapeutics Stock Today
It's easier to invest confidently when you know both the pros and the cons in full.
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
The investment bank analysts who follow these stocks think they can soar even further, with some caveats.
Is Summit Therapeutics a Millionaire Maker?
This company's promising cancer drug could challenge Merck's $25 billion crown jewel.
Could Summit Therapeutics Become the Next Merck?
Recent developments are forcing comparisons between these two drugmakers.
Where Will Summit Therapeutics Be in 3 Years?
There's a lot riding on how its collaborator's studies end up performing.
Has Summit Therapeutics Stock Already Peaked?
Summit Therapeutics stock is up a remarkable 700% this year.
Is Summit Therapeutics Stock a Buy?
Summit Therapeutics is having a great year, and it could realize revenue soon. Its partner Akeso could keep its pipeline packed with late-stage programs.
Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
Viking Therapeutics and Summit Therapeutics both have potential blockbusters on their hands. Their shares have soared this year on the back of strong clinical progress.
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
Summit Therapeutics' stock is way up in response to clinical trial results that suggest the cancer therapy it's developing could become the standard of care for lots of patients. Instil Bio stock soared because it's developing a bispecific antibody similar to the candidate that pushed up Summit Therapeutics.
